CALR and neoplasm: Moreover, tumor PD-L1, PD-1, or PD-L1 im-munotherapy blockade activated NLRP3 leading to resistance in BC as reviewed by our research group [167], highlighting the fact that CALR/NLRP3 and PD-L1/sPD-L1 might provoke an immunosuppressive/resistance loop in BC.